Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

被引：1

作者：

Elder, Mary J. ^{[1
]}

Ashjian, Emily J. ^{[2
]}

机构：

[1] Michigan Med, Pharm Innovat & Partnerships, 2500 Green Rd,Suite 100, Ann Arbor, MI 48105 USA

[2] Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF PHARMACY PRACTICE | 2023年 / 36卷 / 02期

关键词：

diabetes mellitus; glucagon-like peptide-1 receptor agonist; gastric inhibitory polypeptide; G protein-coupled receptor 119 agonist; glucagon receptor agonist; RECEPTOR AGONIST; CHINESE PATIENTS; DOUBLE-BLIND; PHARMACODYNAMICS; PHARMACOKINETICS; SAFETY; METFORMIN; RG7697; SINGLE;

D O I：

10.1177/08971900211049032

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.

引用

页码：418 / 428

页数：11

共 50 条

[31] Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
Sreenivasan, Chithra
Parikh, Aneri
Francis, Aida J.
Kanthajan, Tatchaya
Pandey, Manorama
Alqassab, Osamah
Nath, Tuheen Sankar
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
[32] Glucagon-like peptide-1 (GLP-1):: a gut hormone of potential interest in the treatment of diabetes
Ahrén, B
BIOESSAYS, 1998, 20 (08) : 642 - 651
[33] On the treatment of diabetes mellitus with glucagon-like peptide-1
Holst, JJ
Deacon, C
Toft-Nielsen, MB
Bjerre-Knudsen, L
VIP, PACAP, AND RELATED PEPTIDES: THIRD INTERNATIONAL SYMPOSIUM, 1998, 865 : 336 - 343
[34] Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes
Bak, Ann Mosegaard
Egefjord, Laerke
Gejl, Michael
Steffensen, Charlotte
Stecher, Chalotte Willemann
Smidt, Kamille
Brock, Birgitte
Rungby, Jorgen
EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (10) : 1153 - 1162
[35] The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, Jun
Liu, Yuexing
Jia, Weiping
CHINESE SCIENCE BULLETIN-CHINESE, 2024, 69 (35): : 5094 - 5099
[36] Insulin as a feedback regulator of glucagon-like peptide-1 (GLP-1) release?
Brunn, C
Schloos, J
Lemansky, P
Sewing, S
Mest, HJ
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 : U59 - U59
[37] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
Parab, Panah
Chaudhary, Priti
Mukhtar, Sonia
Moradi, Ali
Kodali, Athri
Okoye, Chiugo
Klein, Dhadon
Mohamoud, Iman
Olanisa, Olawale O.
Hamid, Pousette
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[38] Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay
Lelesz, B.
Toth, G. K.
Peitl, B.
Hegedus, C.
Drimba, L.
Sari, R.
Szilvassy, Z.
Nemeth, J.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2014, 299 (01) : 157 - 164
[39] Description and application of a novel glucagon-like peptide-1 (GLP-1) radioimmunoassay
B. Lelesz
G. K. Tóth
B. Peitl
C. Hegedűs
L. Drimba
R. Sári
Z. Szilvássy
J. Németh
Journal of Radioanalytical and Nuclear Chemistry, 2014, 299 : 157 - 164
[40] Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
Luque, MA
González, N
Márquez, L
Acitores, A
Redondo, A
Morales, M
Valverde, I
Villanueva-Peñacarrillo, ML
JOURNAL OF ENDOCRINOLOGY, 2002, 173 (03) : 465 - 473

← 1 2 3 4 5 →